

**BioSculpture Technology, Inc.** (“BST”) is a commercial stage medical device manufacturer developing a patented and prototyped minimally invasive device for the endoscopic removal of visceral or “belly” fat as a new treatment of obesity, metabolic syndrome and type 2 diabetes mellitus. We believe our method and device will save lives, improve life outcomes, and significantly reduce healthcare costs.

### **The Burgeoning Obesity Problem**

2/3 of the population is overweight and 43% is forecast to be obese in a few years. **US Health** reports there are 2.1 Billion people suffering from obesity about the globe and obesity costs exceed \$2 Trillion USD. 80% of these obese people will develop type 2 diabetes mellitus which is the leading cause of renal failure needing dialysis and a frequent cause of blindness. Obesity doesn’t just shorten your life, but it lessens the quality of it.

### **Market Opportunity**

Obesity related disease expenditures exceeded \$2 Trillion and obesity medical device expenditures exceeded \$1.9 Billion in 2014. **Marketsandmarkets.com** forecasts the obesity market to reach \$17 trillion USD by 2030. There is an enormous unmet need in developed countries and a large potential in lower income countries due to the cost-effective nature of the device for a minimally invasive treatment of obesity which is safer and highly effective.

### **World’s First Direct Removal of the Belly Fat Which Kills You**

Visceral or “belly” fat not only causes sleep apnea and gastric reflux but secretes the cellular hormones that are responsible for all the complications of obesity – diabetes, hypertension, vascular disease, strokes, heart attacks, autoimmune diseases, and cancers. Patented and proprietary methods and devices have been prototyped and are being tested. We believe our device is distinct from and superior to all current or experimental therapies because there is no need to cut into the stomach or bowel, rearrange the alimentary tract, leave behind a foreign body, or be limited by a weight loss plateau. We have been granted three (3) U.S. patents on both method and the device and numerous other patents are pending. Following the successful completion of the current equity offering, we expect our device to become commercially available for “tissue and fluid aspiration, including body sculpting and liposuction” under a 510(k) and subsequently be promoted as a treatment of obesity after clinical trials.

### **Leadership Team**

BST was founded by its Cornell-trained physician founder, Robert L. Cucin, M.D. a serial medical technology entrepreneur who invented this technology and acquired a Columbia MBA to serve as its CEO. His experience includes his being an IP attorney who has successfully licensed his early patents to companies such as Mentor and Ethicon. Its CFO, Deborah Salerno has over 25 years of experience as an investment banker in taking company public, SEC filings and PIPES. The team also has a full complement of technical, clinical and regulatory expertise.

### **Funding and Exit Strategy**

BST plans an IPO to consummate an Offering for \$5,000,000 of common equity and an application for listing on OTC Bulletin Board in Q4 2016/Q1 2017. The use of proceeds will include completion of prototype development and obtaining FDA and preliminary European Union approvals. To defray costs of that Offering, BST is now floating a \$500,000 mezzanine note that carries a 10% coupon and converts at 10% discount at qualification of a Regulation A Offering or an S-1 being declared effective. Additional funding may be required for market expansion and additional regulatory approvals for promotion as an obesity control device. Potential acquirers include companies in the endoscopic and bariatric device sectors.

Investments in this offering shall be restricted solely to accredited investors that have been verified in accordance with rule 506(c) under the securities act of 1933, as amended. This is for information purposes only. The information contained herein does not constitute an offer to sell or a solicitation of an offer to buy any security in BioSculpture Technology, Inc. An offer can be made only pursuant to a written prospectus and only in states in which the offering of these securities is registered or exempt from registration.

**Website:**

[www.evl.technology](http://www.evl.technology)



**Medical Video:**

[https://youtu.be/sVCT1NCz\\_Rw](https://youtu.be/sVCT1NCz_Rw)



**Contact:**

[Robert L. Cucin MD, CEO](#)



Investments in this offering shall be restricted solely to accredited investors that have been verified in accordance with rule 506(c) under the securities act of 1933, as amended. This is for information purposes only. The information contained herein does not constitute an offer to sell or a solicitation of an offer to buy any security in BioSculpture Technology, Inc. An offer can be made only pursuant to a written prospectus and only in states in which the offering of these securities is registered or exempt from registration.

Contact: [ceo@biosculpturetechnology.com](mailto:ceo@biosculpturetechnology.com) [www.evl.technology](http://www.evl.technology) (212) 977-5400